Abstract
Pseudomonas aeruginosa is the most common pathogen infecting the lungs of patients with cystic fibrosis (CF). Improved antimicrobial chemotherapy has significantly increased the life expectancy of these patients. However, accurate susceptibility testing of P. aeruginosa isolates from CF sputum may be difficult because the organisms are often mucoid and slow growing. This study of 597 CF isolates of P. aeruginosa examined the correlation of disk diffusion and Etest (AB BIODISK, Solna, Sweden) results with a reference broth microdilution method. The rates of interpretive errors for 12 commonly used antipseudomonal antimicrobials were determined. The disk diffusion method correlated well (zone diameter versus MIC) for all of the agents tested. However, for mucoid isolates, correlation coefficients (r values) for piperacillin, piperacillin-tazobactam, and meropenem were <0.80. The Etest correlation with reference broth microdilution results (MIC versus MIC) was acceptable for all of the agents tested, for both mucoid and nonmucoid isolates. Category interpretation errors were similar for the disk diffusion and Etest methods with 0.4 and 0.1%, respectively, very major errors (false susceptibility) and 1.1 and 2.2% major errors (false resistance). Overall, both agar diffusion methods appear to be broadly acceptable for routine clinical use in susceptibility testing of CF isolates of P. aeruginosa.
MeSH Terms
Agar
Anti-Bacterial Agents/pharmacology
Child
Cystic Fibrosis/complications,microbiology
Humans
Lung/microbiology
Lung Diseases/diagnosis,microbiology
Microbial Sensitivity Tests/methods
Pseudomonas Infections/diagnosis,etiology
Pseudomonas aeruginosa/drug effects,growth & development,isolation & purification
Reproducibility of Results
Sputum/microbiology
Chemicals
Anti-Bacterial Agents
Agar
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Burns J L
Department of Pediatrics, Division of Infectious Disease, University of Washington, Seattle, Washington, USA.
[email protected]
Saiman L
Whittier S
Larone D
Krzewinski J
Liu Z
Marshall S A
Jones R N
References (12)
12 references, click to expand
-
Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.
Antimicrob Agents Chemother. 1999 Dec;43(12):2877-80
PMID: 10582875
-
Multiple of isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis.
J Infect Dis. 1979 Dec;140(6):873-80
PMID: 120383
-
Pseudomonas aeruginosa: biology, mechanisms of virulence, epidemiology.
J Pediatr. 1986 May;108(5 Pt 2):800-5
PMID: 3009772
-
Biotinylated DNA probes for exotoxin A and pilin genes in the differentiation of Pseudomonas aeruginosa strains.
J Clin Microbiol. 1988 Nov;26(11):2319-23
PMID: 2906943
-
In vitro activity of E-1040, a 3-substituted cephalosporin, against pathogens from cystic fibrosis sputum.
Antimicrob Agents Chemother. 1990 Jul;34(7):1366-70
PMID: 2386368
-
Evaluation of reference dilution test methods for antimicrobial susceptibility testing of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis.
J Clin Microbiol. 1999 Sep;37(9):2987-91
PMID: 10449487
-
The changing epidemiology of cystic fibrosis.
J Pediatr. 1993 Jan;122(1):1-9
PMID: 8419592
-
Management of pulmonary disease in patients with cystic fibrosis.
N Engl J Med. 1996 Jul 18;335(3):179-88
PMID: 8657217
-
Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia.
Microbiol Rev. 1996 Sep;60(3):539-74
PMID: 8840786
-
Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation.
Clin Infect Dis. 1996 Sep;23(3):532-7
PMID: 8879776
-
Microbiology of sputum from patients at cystic fibrosis centers in the United States.
Clin Infect Dis. 1998 Jul;27(1):158-63
PMID: 9675470
-
Resistance to ciprofloxacin of respiratory pathogens in patients with cystic fibrosis.
Med J Aust. 1992 Jan 6;156(1):20-4
PMID: 1734188